Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Giles

Showing results (501-510 of 610) with videos related to

Pageof 61
Sort By:
British Journal of Haematology|November 25, 2003
Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's diseaseFrancis J Giles, Julie M Vose, Kim-Anh Do, et al.
Hematology (Amsterdam, Netherlands)|July 14, 2016
Technetium-99m Sestamibi Scanning Reflects Marrow Activity in a β-Thalassemia Patient Treated with an Allogeneic Bone Marrow TransplantR M Look, H A Koh, S I Hamburg, et al.
Cancer Biology & Therapy|July 11, 2022
Clinical activity of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, in refractory adult T-Cell leukemia/lymphomaAndrew Hsu, Kelsey E Huntington, Andre De Souza, et al.
Leukemia Research|September 9, 2006
Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) projectJune M McKoy, Cara Angelotta, Charles L Bennett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 31, 2004
Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndromeRazelle Kurzrock, Maher Albitar, Jorge E Cortes, et al.
Leukemia Research|December 8, 2005
The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)Francis J Giles, William T Bellamy, Zeev Estrov, et al.
Leukemia|December 12, 2012
FBXW7 regulates glucocorticoid response in T-cell acute lymphoblastic leukaemia by targeting the glucocorticoid receptor for degradationA Malyukova, S Brown, R Papa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2003
Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemiasFrancis J Giles, Stefan Faderl, Deborah A Thomas, et al.
Blood|August 27, 2005
Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemiaStefan Faderl, Kim-Anh Do, Marcella M Johnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2006
Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemiaGail J Roboz, Francis J Giles, Ellen K Ritchie, et al.
Pageof 61

Showing results (501-510 of 610) with videos related to

Sort By:
Pageof 61
British Journal of Haematology|November 25, 2003
Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's diseaseFrancis J Giles, Julie M Vose, Kim-Anh Do, et al.
Hematology (Amsterdam, Netherlands)|July 14, 2016
Technetium-99m Sestamibi Scanning Reflects Marrow Activity in a β-Thalassemia Patient Treated with an Allogeneic Bone Marrow TransplantR M Look, H A Koh, S I Hamburg, et al.
Cancer Biology & Therapy|July 11, 2022
Clinical activity of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, in refractory adult T-Cell leukemia/lymphomaAndrew Hsu, Kelsey E Huntington, Andre De Souza, et al.
Leukemia Research|September 9, 2006
Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) projectJune M McKoy, Cara Angelotta, Charles L Bennett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 31, 2004
Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndromeRazelle Kurzrock, Maher Albitar, Jorge E Cortes, et al.
Leukemia Research|December 8, 2005
The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)Francis J Giles, William T Bellamy, Zeev Estrov, et al.
Leukemia|December 12, 2012
FBXW7 regulates glucocorticoid response in T-cell acute lymphoblastic leukaemia by targeting the glucocorticoid receptor for degradationA Malyukova, S Brown, R Papa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2003
Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemiasFrancis J Giles, Stefan Faderl, Deborah A Thomas, et al.
Blood|August 27, 2005
Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemiaStefan Faderl, Kim-Anh Do, Marcella M Johnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2006
Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemiaGail J Roboz, Francis J Giles, Ellen K Ritchie, et al.
Pageof 61